Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model
- 17 September 2004
- journal article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 12 (2) , 175-184
- https://doi.org/10.1038/sj.cgt.7700777
Abstract
Some anaerobic and facultative anaerobic bacteria have been used experimentally as anticancer agents because of their selective growth in the hypoxia regions of solid tumors after systemic administration. We have previously shown the feasibility of using attenuated Salmonella choleraesuis as a gene delivery vector. In this study, we exploited S. choleraesuis carrying thrombospondin-1 (TSP-1) gene for treating primary melanoma and experimental pulmonary metastasis in the syngeneic murine B16F10 melanoma model. Systemic administration of S. choleraesuis allowed targeted gene delivery to tumors. The bacteria accumulated preferentially in tumors over livers and spleens at ratios ranging from 1000:1 to 10,000:1. The level of transgene expression via S. choleraesuis-mediated gene transfer in tumors could reach more than 1800-fold higher than in livers and spleens. Notably, bacterial accumulation was also observed in the lungs with metastatic nodules, but not in healthy lungs. When administered into mice bearing subcutaneous or pulmonary metastatic melanomas, S. choleraesuis carrying TSP-1 gene significantly inhibited tumor growth and enhanced survival of the mice. Immunohistochemical studies in the tumors from these mice displayed decreased intratumoral microvessel density. Taken together, these findings suggest that TSP-1 gene therapy delivered by S. choleraesuis may be effective for the treatment of primary as well as metastatic melanomas.Keywords
This publication has 32 references indexed in Scilit:
- Angiogenesis, lymphangiogenesis, and melanoma metastasisOncogene, 2003
- Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: Selective inhibitor of angiogenesis and hypoxic tumor growthCancer Gene Therapy, 2003
- Tumor-Targeted Salmonella Expressing Cytosine Deaminase as an Anticancer AgentHuman Gene Therapy, 2002
- Combination bacteriolytic therapy for the treatment of experimental tumorsProceedings of the National Academy of Sciences, 2001
- Radio-responsive recA promoter significantly increases TNFα production in recombinant clostridia after 2 Gy irradiationGene Therapy, 2001
- Prothymosin α enhances protective immune responses induced by oral DNA vaccination against pseudorabies delivered by Salmonella choleraesuisVaccine, 2001
- Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicumCancer Gene Therapy, 2001
- Use of preferentially replicating bacteria for the treatment of cancerJournal of Clinical Investigation, 2000
- Bifidobacterium longum as a delivery system for cancer gene therapy: Selective localization and growth in hypoxic tumorsCancer Gene Therapy, 2000
- Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironmentGene Therapy, 1997